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Endogenous small RNAs (miRNAs) regulate
gene expression by mechanisms conserved
across metazoans. While the number of verified
humanmiRNAs is still expanding, only few have
been functionally annotated. To perform ge-
netic screens for novel functions of miRNAs,
we developed a library of vectors expressing
the majority of cloned human miRNAs and cre-
ated corresponding DNA barcode arrays. In a
screen for miRNAs that cooperate with onco-
genes in cellular transformation, we identified
miR-372 and miR-373, each permitting prolifer-
ation and tumorigenesis of primary human cells
that harbor both oncogenic RAS and active
wild-type p53. These miRNAs neutralize p53-
mediated CDK inhibition, possibly through di-
rect inhibition of the expression of the tumor-
suppressor LATS2. We provide evidence that
these miRNAs are potential novel oncogenes
participating in the development of human tes-
ticular germ cell tumors by numbing the p53
pathway, thus allowing tumorigenic growth in
the presence of wild-type p53.
INTRODUCTION
Since their discovery, the functions of only a handful of
microRNAs (miRNAs) have been determined (recently re-
viewed in Zamore and Haley, 2005). Relevant to carcino-
genesis, it was found that let-7 inhibits RAS expression
and in lung tumors negatively correlates with RAS levels
(Johnson et al., 2005). Furthermore, the oncogenic poten-Ctial of the miR-17-92 cluster was demonstrated (He et al.,
2005; O’Donnell et al., 2005). This cluster is amplified in
lymphomas (Ota et al., 2004), and its introduction acceler-
ates tumorigenicity by an as yet undefined process. These
findings demonstrate the powerful ability of small RNAs
to alter cellular pathways and programs. However, the
small number of miRNAs with a known function stresses
the need for a systematic screening approach to identify
more miRNA functions.
The difficulties in deciphering the mechanism of action
of miRNAs with a known function and deducing their activ-
ity from their sequence are largely due to the complex re-
lationship with their target genes. In general, target genes
containing sequences that are completely complementary
to the miRNA will be degraded by an RNA-interference
mechanism, whereas targets with partial complementary
sequences at their 30UTR will be subjected to translation
inhibition and to a lesser extent also to mRNA degradation
(Doench and Sharp, 2004; Bagga et al., 2005; Lim et al.,
2005; Pillai et al., 2005). In mammals, a near-perfect com-
plementarity between miRNAs and protein coding genes
almost never exists, making it difficult to directly pinpoint
relevant downstream targets of a miRNA. Several algo-
rithms were developed that predict miRNA targets, most
notably TargetScanS, PicTar, and miRanda (John et al.,
2004; Lewis et al., 2005; Robins et al., 2005). These pro-
grams predict dozens to hundreds of target genes per
miRNA, making it difficult to directly infer the cellular path-
ways affected by a given miRNA. Furthermore, the biolog-
ical effect of the downregulation depends greatly on the
cellular context, which exemplifies the need to deduce
miRNA functions by in vivo genetic screens in well-defined
model systems.
The cancerous process can be modeled by in vitro neo-
plastic transformation assays in primary human cells
(Hahn et al., 1999). Using this system, sets of genetic
elements required for transformation were identified. Forell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1169
example, the joint expression of the telomerase reverse
transcriptase subunit (hTERT), oncogenic H-RASV12, and
SV40-small t antigen combined with the suppression of
p53 and p16INK4A were sufficient to render primary human
fibroblasts tumorigenic (Voorhoeve and Agami, 2003).
Recently, these neoplastic transformation assays were
used to uncover novel human tumor suppressor genes
(Kolfschoten et al., 2005; Westbrook et al., 2005).
Moreover, oncogenes such as H-RASV12 provoke
a stress response in primary cells that results in an irre-
versible growth arrest, termed premature senescence
(Serrano et al., 1997). The senescent phenotype was re-
cently shown to play a role in the protection from tumor
development in vivo (Braig et al., 2005; Chen et al.,
2005; Collado et al., 2005; Michaloglou et al., 2005). The
elimination of this protective mechanism by, for example,
the suppression of the p53 and p16INK4A pathways per-
mits continued proliferation of the modified primary cells
in the presence of the oncogenic event, consequently
leading to tumorigenicity (Voorhoeve and Agami, 2003).
Here, we use this model system to perform a functional
genetic screen to identify miRNAs that act as oncogenes
in tumorigenesis. We characterize two miRNAs whose ex-
pression can substitute for the loss of wild-type (wt) p53
that is needed to overcome oncogene-mediated arrest
and implicate their involvement in the formation of testic-
ular germ cell tumors.
RESULTS
miR-Vec: A Vector-BasedmiRNAExpression System
To identify novel functions of miRNAs, we constructed
a retroviral vector for miRNA expression (miR-Vec) follow-
ing a previously described approach (Chen et al., 2004).
We inserted 500 bp fragments spanning a given
miRNA-genomic region in a modified pMSCV-Blasticidin
vector such that they are placed under the control of a
CMV promoter (Figure 1A). To examine miRNA expression
from the miR-Vec system, a miR-24 minigene-containing
virus was transduced into human cells. Expression was
determined using an RNase protection assay (RPA) with
a probe designed to identify both precursor and mature
miR-24 (Figure 1B). Figure 1C shows that cells transduced
with miR-Vec-24 clearly express high levels of mature
miR-24, whereas little expression was detected in con-
trol-transduced cells. Furthermore, we confirmed the con-
sistency of miRNA expression driven by miR-Vec by
cloning eight miR-Vec plasmids expressing randomly
chosen miRNAs. With one exception, all constructs
yielded high expression levels of mature miRNAs (Fig-
ure S1). Notably, very little pre-miRNA accumulation was
detected in all cases, indicating the efficient processing
of the ectopically expressed miRNAs in the cells.
Next, we examined the functionality of the miR-Vec sys-
tem to suppress gene expression by using both GFP,
tagged with a sequence complementary to miR-19, and
luciferase containing either the wt 30UTR of G6PD, a pre-1170 Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc.dicted miR-1 target, or control with two mutated miR-1
binding sequences (Lewis et al., 2003). Using fluores-
cence microscopy and luciferase assays, we observed
potent and specific miRNA activity expressed from each
miR-Vec (Figure S2). These results demonstrate the gen-
eral applicability of miR-Vec to drive functional miRNA
expression.
miR-Lib and miR-Array
We subsequently created a human miRNA expression
library (miR-Lib) by cloning almost all annotated human
miRNAs into our vector (Rfam release 6) (Figure S3). Addi-
tionally, we made a corresponding microarray (miR-Array)
containing all miR-Lib inserts, which allows the detection
of miRNA effects on proliferation.
To test the sensitivity of screens with miR-Lib and miR-
Array, we transduced modified primary BJ fibroblasts ex-
pressing ecotropic receptor and immortalized with hTERT
(BJ/ET) with a mixture of 197 different miR-Vecs and
mixed them in a ratio of 400:1 with BJ/ET cells containing
both miR-Vec-311 and a knockdown construct for p53
(p53kd) (Figure 1D). Previously, we have shown that in a
period of 2 weeks BJ/ET-p53kd cells increase 4- to
5-fold in number compared with BJ/ET cells (Voorhoeve
and Agami, 2003). In accordance, we observed an ap-
proximately 4-fold increase in miR-311 signal, indicating
that our procedure is sensitive enough to detect mild
growth differences (Figure 1E).
Expression of miR-372 and miR-373 Protects from
Oncogenic Stress
In response to mitogenic signals from oncogenes such as
RASV12, primary human cells undergo a growth arrest (Fig-
ure 2A) (Serrano et al., 1997). In contrast, primary cells
lacking functional p53 efficiently overcome this arrest.
This escape from oncogene-induced senescence is a pre-
requisite for full transformation into tumor cells. To identify
miRNAs that can interfere with this process and thus might
contribute to the development of tumor cells, we trans-
duced BJ/ET fibroblasts with miR-Lib and subsequently
transduced them with either RASV12 or a control vector
(Figure 2B). After 2 or 3 weeks in culture, senescence-in-
duced differences in abundance of all miR-Vecs were de-
termined with the miR-Array. Figures 2C and S3 show that
in three independent experiments the relative abundance
of three miR-Vecs increased reproducibly in the RASV12-
expressing population. These hits corresponded to three
constructs derived from one genomic region expressing
miRNAs 371, 372, 373, and 373* (Figure 2D). Due to the
close proximity of miR-371 and miR-372 in the genome
(within 0.5 kilobase), two largely overlapping constructs
encoded both miRNA-371 and 372 (miR-Vec-371&2).
The third construct did not overlap with miR-Vec-371&2
and encoded miRNA-373 and 373*. Interestingly, the ma-
ture miR-373 is a homolog of miR-372, and neither shares
obvious homology with either miRNA-371 or miR-373*
(Figure 2D). This suggests that miR-372 and miR-373
caused the observed selective growth advantage.
Figure 1. Tools for Functional Genetic Screens with Human miRNAs
(A) The miR-Vec miRNA-expressing system. Transcription of the minigene mimics the pri-miRNA, which is subsequently processed to a mature
miRNA.
(B) The RPA technique used to detect precursor and mature miRNAs in this study.
(C) RPA was performed on RNA extracts from primary human BJ cells stably transduced with miR-Vec-24 and miR-Vec-ctrl. We used a probe to
cyclophilin to control for loading. (P = 10% input probe, Y = Yeast control RNA).
(D and E) BJ/ET-p53kd cells were transduced with miR-Vec-311, and BJ/ET cells were transduced with a mix of 197 other miR-Vecs. Both populations
were drug selected, mixed in a ratio of 1:400, and left to grow for 2 weeks. A barcode experiment was done comparing cells right after mixing (t0) and
after 2 weeks in culture (t2). The log2 of the ratio of the signals between t2 and t0 was plotted against the average signal to visualize outliers. The signal
derived from the spot corresponding to Mir-311 is indicated in pink.Next, we verified miRNA function in a cell-growth assay.
First, we verified the expression of both miR-371 and 372
by miR-Vec-371&2 and miR-373 by miR-Vec-373 (Fig-
ure 2E). We then transduced BJ/ET cells with miR-Vec-
371&2, miR-Vec-373, or the controls p53kd and vector
control and then with RASV12. As expected, control cells
ceased proliferating in response to RASV12, whereas
p53kd cells continued to proliferate (Figure 2F). The ex-
pression of either miR-371&2 or miR-373 allowed cells
to continue proliferating in the presence of oncogenic
stress, validating the effect observed with the miR-Array.
Oncogene-induced senescence is characterized by the
appearance of cells with a flat morphology that express
senescence associated (SA)-b-Galactosidase. Indeed,
control RASV12-arrested cells showed relatively high abun-
dance of flat cells expressing SA-b-Galactosidase (Fig-
ures 2G and 2H). Consistent with the cell growth assay,
very few cells showed senescent morphology when trans-
duced with either miR-Vec-371&2, miR-Vec-373, or con-
trol p53kd. Altogether, these data show that transduction
with either miR-Vec-371&2 or miR-Vec-373 prevents
RASV12-induced growth arrest in primary human cells.CThe independent identification of constructs encoding
two very similar miRNAs (miR-372 and miR-373) suggests
that they (but not miR-371 or miR-373*) are required to
cause this phenotype. To test this, we mutated the se-
quences of miR-372 and miR-373. As demonstrated by
RPA, miR-Vec-372mut and miR-Vec-373mut indeed failed
to express miR-372 and miR-373, respectively (Figure 3A).
Note that miR-Vec-372mut still expressed miR-371 to
a similar extent as the original miR-Vec-371&2. We then
tested these constructs in a YFP-competition assay to
detect possible growth advantages conferred by the
miRNAs on BJ cells in the absence or presence of RASV12
(Figure 3B). For this purpose we used a miR-Vec vector
that expresses YFP instead of a blasticidin resistance
marker and compared the growth rates of YFP-tagged
and untagged cells within one population. Increase in
time of the YFP-positive cells within the population indi-
cates a growth advantage conferred by the additional ge-
netic unit encoded by the YFP vector. We also generated
BJ/ET cells expressing the RASV12-ERTAM chimera gene,
which is only active when tamoxifen is added (De Vita
et al., 2005), and tranduced them with either YFP-taggedell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1171
Figure 2. Identification of miR-Vecs that Inhibit Oncogene-Induced Senescence
(A) The effects of oncogenic RASV12 on cellular growth.
(B) A flow chart of the screen. Cells transduced with the miR-Lib were grown for 2 to 3 weeks in the presence or absence of RASV12. Subsequently,
the population of inserts in each condition was recovered and compared using miR-array.
(C) Three independent miR-Array experiments were performed. The position of the reproducibly upregulated miR-Vecs is indicated for each experiment.1172 Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc.
wt or mutant miR-Vec-371&2 and miR-Vec-373 con-
structs as well as p53kd, p14ARFkd, or control vectors.
Figure 3B shows that even without activating RASV12 (no
tamoxifen added), both miR-Vec-371&2 and miR-Vec-
373 conferred a growth advantage to cells, although to
a lesser extent than observed with p53kd or p14ARFkd.
Once RASV12 was activated, the growth advantage of cells
with miR-Vec-371&2 and 373 increased dramatically, indi-
cating that these constructs allowed growth of cells in the
presence of oncogenes while the rest of the population
ceased to proliferate. In accordance with previously pub-
lished data (Voorhoeve and Agami, 2003), reducing p53,
but not p14ARF expression, was sufficient to overcome
the oncogenic stress. Consistent with our assumption
that miR-372&3 are the active miRNAs, mutating their ma-
ture sequence abrogated their growth advantage. This
shows that miR-372&3, but not miR-371 or miR-373*,
caused stimulation of proliferation and resistance to onco-
genic stress.
Expression of miR-372 and miR-373 Transforms
Primary Human Cells
Suppression of cellular senescence is essential for tumor-
igenesis. We therefore examined whether the ectopic
expression of miR-372/3 is sufficient to replace loss
of p53 in transformation of cells. A hallmark of cellular
(D) The miR-371-3 genomic organization and the sequences of the mature miRNAs expressed from this locus. For comparison, the nucleotides 2–8
(seed) of the miRNAs are boxed.
(E) RPA analysis of RNA from BJ/ET cells containing the indicated miR-Vecs.
(F) BJ/ET cells containing the indicated vectors were transduced with RASV12, drug selected, and subjected to a growth assay. Standard deviations
from three independent transductions are shown.
(G) The cells from (F) were stained 10 days after RASV12 transduction to detect SA-b-galactosidase expression.
(H) The percentage of b-galactosidase positive cells was counted in three independent dishes.
Figure 3. miR-372&3 Collaborate with Oncogenic RASV12 to Transform Primary Human Cells
(A) The mature miR-372&3 sequences were mutated in their corresponding miR-Vecs, and their expression was examined by RPA. miR-Vec cluster is
a construct encompassing miRs-371-3.
(B) The indicated YFP-containing vectors were transduced in BJ/ET-RASV12-ERTAM cells. The cumulative growth advantage was determined in the
absence or presence of tamoxifen (+RASV12).
(C and D) BJ/ET cells containing SV40 small t, p16INK4A knockdown, RASV12, and the indicated constructs were plated in soft agar, and colonies were
photographed and counted after 3 weeks. The average and standard deviation of three independent dishes is shown.
(E) The cluster, p53kd, and control cell populations from (C) were injected subcutaneously in athymic nude mice, and tumor growth was scored 5
weeks later.Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1173
transformation is the ability of tumor cells to grow anchor-
age independently in semisolid medium and as tumors in
model mice (Hahn et al., 1999; Hanahan and Weinberg,
2000). Indeed, in a soft agar assay, modified primary
human BJ/ET cells expressing hTERT, SV40-small t,
RASV12, and shRNA-knockdowns for p53 and p16INK4A
showed potent ability to grow in an anchorage-indepen-
dent manner (Figures 3C and 3D). To mimic the expres-
sion of the complete miR-371-373 gene cluster, we
made a miR-Vec expressing all miRNAs from one cluster
(miR-Vec-cluster; see Figure 3A for expression). Similar
to the knockdown of p53, the ability to grow in soft
agar was also observed for cells containing miR-Vec-
cluster, miR-Vec-371&2, or miR-Vec-373 but not miR-
Vec-372mut or miR-Vec-373mut (Figures 3C and 3D). More-
over, the cells containing the miR-371-373 cluster grew
efficiently as tumors in athymic nude mice (Figure 3E).
These results demonstrate that miR-372&3 collaborate
with RAS in transformation in a manner that resembles
p53 inactivation.
Importantly, our results so far indicate that the expres-
sion of miR-372&3 did not reduce the activity of RASV12,
as these cells were still growing faster than normal cells
and were tumorigenic, for which RAS activity is indispens-
able (Hahn et al., 1999; Kolfschoten et al., 2005). There-
fore, the miRNA-mediated circumvention of the activation
of p53 can in principle be obtained at a level upstream of
p53, on p53 itself, or downstream. To shed more light on
this aspect, we examined the effect of miR-372&3 expres-
sion on p53 activation in response to oncogenic stimula-
tion. We used for this experiment BJ/ET cells containing
p14ARFkd because, following RASV12 treatment, in those
cells p53 is still activated but more clearly stabilized than
in parental BJ/ET cells (Voorhoeve and Agami, 2003), re-
sulting in a sensitized system for slight alterations in p53
in response to RASV12. Figure 4A shows that following
RASV12 stimulation, p53 was stabilized and activated,
and its target gene, p21cip1, was induced in all cases, indi-
cating an intact p53 pathway in these cells. Therefore, it
is unlikely that the miRNAs act on a factor upstream of
p53 or on p53 itself to suppress the cellular response to
oncogenic RAS.
Increased levels of p21cip1 inhibit CDK activity, causing
cells to arrest in G1 phase (el-Deiry et al., 1993), whereas
suppression of p21cip1 allows cells to grow in the presence
of RASV12 (Figure S4A). To test whether p21cip1 was still
functional in the miRNA-transduced cells, we examined
CDK2 activity using an IP-Kinase assay (Figure 4B). In
both miR-372&3-expressing cells, CDK2 remained active
following RASV12 induction, whereas it was inhibited in the
control cells (Figure 4B). In contrast, miR-372&3-trans-
duced cells were still sensitive to inhibition of CDK activity
by roscovitin (Figure S4B). This indicates that the pres-
ence of miR-372/3 acts as a molecular switch to make
CDK2 resistant to increased levels of the cell cycle inhib-
itor p21cip1.
Both p53 and p21cip1 play a major role in the DNA dam-
age response to ionizing radiation (IR) (Weinert, 1998).1174 Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc.Since cells expressing miR-372&3 proliferate in the pres-
ence of increased p21cip1 levels, we examined their re-
sponse to damaged DNA. In the presence of both miRNAs,
and irrespective of RASV12 expression, IR induced a cell
cycle arrest that was indistinguishable from control cells,
whereas the suppression of p53 expression allowed, as
expected, continuous DNA replication (Figure 4C and data
not shown). These results indicate that although miR-
372&3 confer complete protection to oncogene-induced
senescence in a manner similar to p53 inactivation, the
cellular response to DNA damage remains intact.
Potential Role of miR-372 and miR-373 in Human
Cancer
Based on the above results, we hypothesized that miRNA-
372&3 may participate in tumorigenesis of some tumors
that retain wt p53 and are sensitive to DNA-damaging
treatments. One such tumor type is the testicular germ
cell tumor of adolescents and adults (TGCT), known for
the presence of wt p53 in the majority of cases and known
to be generally sensitive to chemotherapies as well as irra-
diation (Kersemaekers et al., 2002; Masters and Koberle,
2003; Mayer et al., 2003). In addition, these tumors har-
bour an embryonic stem (ES) cell signature (Almstrup
et al., 2004), which correlates with the reported ES-cell ex-
pression pattern of the miR-371-3 cluster (Suh et al.,
2004). We therefore examined a number of cell lines orig-
inating from TGCTs for the expression of the miR-371-3
cluster. Four out of seven cell lines expressed this cluster
(Figures 4D and S5). This result is significant as no clear
expression of the miR-371-3 cluster was detected in any
of the somatic cell lines we tested (originating from breast,
colon, lung and brain tumors) (Figure S6).
TGCTs are divided into seminomas, non-seminomas,
and spermatocytic-seminoma, according to their origin,
clinical behavior, and chromosomal constitution (Ooster-
huis and Looijenga, 2005). The nonseminomas can be
composed of embryonal carcinoma (EC, the stem cell
component), teratocarcinoma (TC, somatic differentia-
tion), and yolk sac tumor and choriocarcinoma (YS and
CH, extra-embryonal tissues). All the cell lines we tested
were derived from nonseminomatous tumors, as there
are no other type of TGCT cell lines available so far. To
substantiate our results and extend them to other TGCT
types, we examined a panel of primary seminomas, non-
seminomas, and spermatocytic seminomas for the ex-
pression of miR-372. Figures 4D and S7 show that most
seminomas (28/32) had a clear miR-372 expression, that
about two thirds (14/21) of the nonseminomas expressed
miR-372, and that expression was observed in neither
RNA from the spermatocytic-seminoma tumors (data not
shown) nor from the normal testis tissue panel. Notewor-
thy is the fact that endogenous expression of miR-372
reached levels that are comparable to those driven by
miR-Vec-372 (Figure 4D), indicating the biological rele-
vance of our system in primary human fibroblast cells.
Within the nonseminoma samples, both pure and mixed
histologies were present (Figure S7). The RPA analysis
Figure 4. miR-372 and miR-373 Sustain CDK2 Activity in TGCT
(A) BJ/ET-p14ARFkd-RASV12ERTAM cells containing the indicated miR-Vecs were cultured for a week in the presence or absence of tamoxifen (TAM),
harvested, and subjected to immunoblot analyses to detect p21cip1, p53, and RASV12ER.
(B) The same polyclonal populations as in (A) were harvested, and CDK2 kinase activity was measured using an IP-kinase protocol with Histone H1 as
a substrate. Equal pulldown of CDK2 was checked by immunoblot of the same samples (lower panel).
(C) BJ/ET cells containing either a control vector (BJ), or the indicated constructs were irradiated (4 Gy), labeled with BRDU, and subjected to flow
cytometric analysis. The percentage of BRDU positive cells relative to the unirradiated cells is shown. SD is from three independent experiments.
(D) The expression of miR-372 was detected by RPA in RNA extracts from several TGCT cell lines as well as from primary seminoma and nonsemi-
noma tumors and from normal testis tissues.
(E) In situ hybridization on a nonseminoma of mixed histology to detect miR-372&3 expression. The probe was developed with NBT/BCIP blue, and
the section was counterstained with FastRed. The EC component of the tumor was morphologically determined using HE-counter staining and by
immunohistochemistry with anti-CD30 and OCT3/4 antibodies of the next sections.
(F) Summary of the p53 status in several TGCT cell lines and primary seminomas (in the latter, only exons five to eight were examined).
(G) NCCIT cells were cotransfected with H2B-GFP and the indicated constructs. Cell-cycle profiles of the GFP-positive population were examined
after 4 days using flow cytometry. Also shown is an immunoblot analysis of cells from the same experiment with antibodies against p21cip1, CDK2, and
cyclin E.showed that high expression of miR-372 correlated with
a larger EC component. To further investigate this connec-
tion, we performed in situ miRNA hybridizations on tissue
sections of 10 representative TGCTs and found in all
cases 372&3 to be strictly localized to the EC component,
as judged by morphology and immunohistochemistry with
CD30 and Oct3/4 (Figure 4E and data not shown). Both
seminomas and the EC component of nonseminomasCeshare features with ES cells. To exclude that the detection
of miR-371-3 merely reflects its expression pattern in ES
cells, we tested by RPA miR-302a-d, another ES cells-
specific miRNA cluster (Suh et al., 2004). In many of the
miR-371-3 expressing seminomas and nonseminomas,
miR-302a-d was undetectable (Figures S7 and S8), sug-
gesting that miR-371-3 expression is a selective event
during tumorigenesis.ll 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1175
Interestingly, we noted a correlation between cluster ex-
pression and p53 status in the TGCT cell lines (Figure 4F).
Whereas all three cluster-expressing cell lines contained
high wt-p53 levels, NTera2 has low wild-type p53 levels,
and NCCIT lost one p53 allele while the second allele
is mutated (Burger et al., 1998). To strengthen the p53
connection seen in the TGCT cell lines, we examined
p53 mutations in exons five to eight in the primary tumors,
where the majority of mutations are found. In the nonsemi-
noma panel, no mutations were detected. In contrast, two
out of four miRNA 372-negative seminomas had an inac-
tivating mutation in the p53 gene (SE20 in exon 8 and
SE28 in exon 5; Figures 4F and S7), a rare phenomenon
in TGCT (Kersemaekers et al., 2002). In contrast, none of
the 13 miRNA 372&373-expressing seminomas that we
examined contained mutations in p53. Altogether, these
results strongly suggest that the expression of miR-372/
3 suppresses the p53 pathway to an extent sufficient to
allow oncogenic mutations to accumulate in TGCTs.
We then decided to test directly the correlation between
the p53 pathway and miR-372/3 expression in TGCTs. It
was technically not possible to sufficiently and persis-
tently inhibit the expression of both miR-372 and miR-
373 by methylated miRNA-oligos or knockdown vectors
against the loop of the precursors (as judged by miR-
372 and miR-373 luciferase reporter targets; data not
shown). As an alternative approach, we used NCCIT, an
embryonal carcinoma-derived cell line containing only
a mutated, nonfunctional p53 that expresses very low
amounts of the miR-371-3 cluster (Figure 4D) (Burger
et al., 1998). We activated the p53 pathway by transfecting
NCCIT cells with a p21-RFP construct that inhibits Cyclin
E/CDK2 activity and examined the effects of miR372/3
by cotransfecting miR-Vec-371-3 (cluster). As expected,
overexpression of p21-RFP caused accumulation of cells
in G1, whereas cotransfection of Cyclin E/CDK2 allowed
cells to continue proliferating in the presence of p21-
RFP (Figure 4G). Significantly, cells cotransfected with
the miR-Vec-cluster showed a phenotype similar to that
observed with Cyclin E/CDK2. This result demonstrates
the ability of miR-372 and miR-373 to overcome a p21-
mediated cell cycle arrest in TGCTs and substantiates
the correlation between these miRNAs, CDK and the
p53 pathway.
miR-372 andmiRNA-373 Regulate LATS2 Expression
Our results thus far indicate that miR-371-3 cluster sup-
presses an inhibitor of CDK activity and that this function
is important for the development of TGCTs. To start to
identify relevant targets of miR-372&3, we took advantage
of the fact that miRNAs may cause limited destruction of
their target mRNAs apart from inhibiting their translation
(Lim et al., 2005). We performed an mRNA-expression
array analysis comparing RASV12-expressing BJ/ET cells
either containing p53kd or expressing the miR-371-3 clus-
ter (Figures 5A and S9). We chose this setup as both cell
types proliferate in the presence of oncogenic stress,
thus canceling out the profound effects of cells going1176 Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc.into senescence. We first looked in the p53kd cells and
found p53 itself and many of its transcriptional targets to
be downregulated compared to the cluster-expressing
cells (Figure 5A). This independently confirms our previous
results (Figure 4A) indicating that miR-372&373 do not di-
rectly inhibit p53 activity. From the list of genes whose ex-
pression was 2- or more fold lower in the cluster-express-
ing cells, we used target prediction programs to find
possible direct targets of miR-372&3. We identified three
miR-372/3 predicted targets: FYCO1 (FYVE and coiled
coil containing protein 1), Suv39-H1, and LATS2 (Fig-
ure 5A). Interestingly, while nothing is known on the func-
tion of the FYCO1 protein, both Suv39-H1 and LATS2
have been connected in the past to RASV12-mediated
transformation. It was recently shown that lymphocytes
from mice nullizygous for Suv39-H1 are resistant to onco-
gene-induced senescence (Braig et al., 2005). However,
the mechanism underlying this effect and its conservation
to other tissues and to man are not known. Most promis-
ing seemed the LArge Tumor Suppressor homolog 2
(LATS2), a serine-threonine kinase whose deletion in flies
accelerates cellular proliferation and tumorigenic devel-
opment (Justice et al., 1995; Xu et al., 1995). In mice, a
similar activity was seen in LATS2/ mouse embryonic
fibroblasts (McPherson et al., 2004), whereas its overex-
pression was shown to inhibit cyclin E/CDK2 activity and
RASV12-mediated transformation (Li et al., 2003). Addi-
tionally, loss of LATS2 stimulated reduplication, an activity
comparable to that observed when Cyclin E is over-
expressed in the absence of p53 (Fukasawa et al., 1996;
Tarapore and Fukasawa, 2002; Toji et al., 2004). Finally,
in human breast cancer, hypermethylation of the LATS2
promoter was associated with an aggressive phenotype
of the tumors (Takahashi et al., 2005). These observations
suggest that the suppression of LATS2 explains at least in
part the sustained activity of CDK in the presence of high
p21cip1 levels in miR-372/3-expressing cells.
To investigate the possibility that miR-372 and miR-373
suppress the expression of LATS2, we performed immu-
noblot analysis of cells expressing wt and mutant miR-
372&3, the cluster and the controls p53kd and empty vec-
tor. Both in the absence of RASV12 and in its presence,
a significant reduction in LATS2 protein level was ob-
served upon miR-372&3 expression (Figure 5B). Using
quantitative RT-PCR and immunoblot analysis, we ob-
served a 2-fold effect on LATS2 RNA levels and 4- to 5-
fold on protein levels by the miR-371-3 cluster (Figure 5C).
As a control, we used a LATS2 knockdown construct (Fig-
ure 5F). These results show that a combined effect of RNA
destruction and translation inhibition is used by miR-
372&3 to silence LATS2.
miR-372/3 was predicted to bind two sites in the 30UTR
of LATS2 that are highly conserved between human,
mouse, and zebrafish (Figure 5D). To further substantiate
LATS2 as a direct target of miR372&3, we cloned its 30UTR
downstream of the firefly luciferase gene (pGL3-LATS2).
We transfected either pGL3-LATS2 or the controls pGL3-
372 and pGL3-373 (containing a miR-complementary
Figure 5. Inhibition of LATS2 Expression by miR-372 and miR-373
(A) RNA was extracted from BJ/ET cells expressing RASV12 and containing either a p53kd construct or miR-Vec-371-3 (cluster) and compared using
oligo-expression arrays (Figure S9). Listed are genes whose expression was downregulated in the p53kd cells and are known transcriptional targets of
p53 as well as genes whose expression was suppressed in the cluster-expressing cells and are predicted TargetScanS targets of miRNA-372&3.
LATS2*: The reduction was verified by Q-RT-PCR (Figure S10).
(B and C) BJ/ET cells containing the indicated constructs were analyzed by immunoblot analysis or by Q-RT-PCR. Band intensity was calculated by
densitometry.
(D) The 30-UTRs of LATS2 in human (Hs), mouse (Mm), and zebrafish (Dr) are shown, and the predicted miR-372&3 target sequences are marked.
(E) The indicated vectors were transfected in miR-372&3-positive (Tera1) and negative (MCF-7) cell lines. The relative firefly luciferase levels (divided
to Renilla control and compared to pGL3) are shown. SD are from three independent experiments.
(F) Cumulative growth advantage assay was performed as described in Figure 3B in RASV12-expressing cells transduced with the indicated vectors.
For comparison, data from Figure 3B are included (dashed lines). An accompanying immunoblot shows that only LATS2kd#2 is functional.
(G) A schematic model showing the mechanism through which miR-372&3 can suppress an oncogene-activated p53 pathway.Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1177
sequence in their 30UTR) or pGL3 into Tera1 and MCF-7
cells (respectively positive and negative for miR-371-3)
(Figures 4D and S6). As predicted, the 372/373 comple-
mentary sequences mediated strong inhibition of lucifer-
ase expression in Tera1 cells. Significantly, a potent inhi-
bition of luciferase activity was also mediated by the
30UTR of LATS2 in either MCF-7 ectopically expressing
miR-372 or in Tera1 cells but not by a construct mutated
at both miR-372-predicted target sites. These results indi-
cate that LATS2 is indeed a direct target of miR-372&3.
Next, we tested whether LATS2 is a functional target
of miR-372&3 using a YFP-competition assay. Indeed, in-
hibition of LATS2 conferred a growth advantage to cells
expressing RASV12 (Figure 5F). The overall effect was
less than the effect of the miR-Vec 373 but comparable
to loss of p53. Therefore, these results point to LATS2 as
a mediator of the miR-372 and miR-373 effects on cell
proliferation and tumorigenicity, although they do not ex-
clude the participation of other direct miR-targets, such
as Suv39-H1, in these processes. Further investigation
should elucidate the exact role of LATS2 downregula-
tion and the possible participation of other miR-372&3-
targets in the overall observed miR effect on cellular
transformation.
DISCUSSION
Functional Genetic Screens for miRNAs
We developed a miRNA-expression vector library and
a corresponding barcode array to detect miRNAs whose
expression modifies a defined cellular pathway. We dem-
onstrate here the power of this technology by the identifi-
cation of miRNA-372 and miRNA-373 as potential onco-
genes that collaborate with oncogenic RAS in cellular
transformation (Figure 5G). However, this strategy is also
suitable for the identification of miRNAs that regulate other
cellular pathways resulting in a proliferation or survival dif-
ference, such as the DNA damage response, differentia-
tion, sensitivity to growth factors, and resistance to anti-
cancer drugs. Furthermore, the miR-Lib tool can be used
in a single-well format to identify growth-independent
phenotypes.
Collaboration of miRNA372&3 and RASV12
in Tumorigenesis
Sustained proliferation of cells in the presence of onco-
genic signals is a major leap toward tumorigenicity (Hana-
han and Weinberg, 2000). We found miR-372&3 to collab-
orate with RASV12 and stimulate a full-blown neoplastic
transformation phenotype. However, whereas in the
majority of the cases neoplastic transformation will require
inactivation of p53 (for example by expression of HPV E6,
HDM2, or mutant p53), miR372&3 uniquely allowed trans-
formation to occur while p53 was active. This indicates
that miRNA-372&3 do not block RASV12 signals but rather
allow cells to proliferate irrespective of p53 activation and
induction of p21cip1.1178 Cell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc.The expression of miR-372&3 results in prevention of
the CDK inhibition that is caused by the oncogenic stress
response. In both primary human fibroblasts and in a
TGCT-derived cell line, cells expressing miR-372&3 were
insensitive to elevated levels of the cell-cycle inhibitor
p21cip1. Although the exact mechanism responsible for
this effect is still unclear, we suggest that suppression of
LATS2 is an important factor. Indeed, the expression of
LATS2 is directly controlled by miR-372&3, and its activity
is important for RASV12-induced senescence. However,
further investigation is required to demonstrate the exact
mechanism of LATS2 action and whether there are other
targets of miR-372&3, such as Suv39H1, that are relevant
to this phenotype.
Correlations to Other miRNAs
Based on the seed sequence, the miR-372&3 gene family
also includes miR-93 and miR-302a-e. As these may
share a broad range of target genes, they may also share
many functions. Indeed, preliminary results show that
similar to miR-372&3, albeit with minor differences, both
miR-93 and miR-302a-e can effectively target the LATS2
30UTR and bypass oncogene-induced senescence (man-
uscript in preparation).
Role of miR372&3 in TGCT Development
Our results suggest that during transformation, the activi-
ties of miR-372&3 circumvented the need to mutate p53,
leading to a DNA-damage-sensitive transformed pheno-
type. These characteristics of miR-372&3-transformed
primary human cells therefore suggest a role in wt p53-
tumor genotypes that are also sensitive to chemother-
apies, including irradiation. Indeed, TGCTs conform to
this profile (Masters and Koberle, 2003). This could for in-
stance be a result of high mdm2 levels, as was previously
suggested for mouse teratocarcinomas (Lutzker and Lev-
ine, 1996). However, by several criteria mouse teratocarci-
nomas are counterparts of human germ cell tumors of
neonates and infants rather than TGCT (Oosterhuis and
Looijenga, 2005). Indeed, while the first show high mdm2
expression levels, this was not demonstrated in TGCT
(Mostert et al., 2000). Therefore, it is highly significant
that we found that miR-372&3-expressing TGCTs did not
contain mutated p53 alleles, whereas a subset of miR-
371-3 negative primary TGCTs and cell lines did. Alto-
gether, these provide a strong indication that there is no
selective advantage to mutate p53 during TGCT develop-
ment when the miR-371-3 cluster is expressed.
The potent role of miR-372&3 in cellular transformation
and potentially in TGCT development raises the possibility
that they may play a similar role in somatic tumors. To this
end, we determined the expression of the miR-371-3 clus-
ter in several distinct somatic tumor cell lines and found lit-
tle evidence for their expression (Figure S6). Consistent
with our results, clear miR-371-3 cluster expression was
observed in only 1 out of 70 leukemia tumors examined
by others (Lu et al., 2005). It therefore seems that miR-
372&3 expression is a rare event in somatic tumors.
Whether such a role can be seen with the other members
of the miR-372/3 family remains an open possibility.
Although both miR-372&3 and miR-302a-e clusters are
expressed in ES cells (Suh et al., 2004), the miRNA-302
cluster is not expressed in many of these primary semino-
mas and nonseminomas (Figure S7). It is therefore most
likely that the expression of miR-371-3 in primary TGCT
is not merely a remnant of their ES cell phenotype but
rather a selective event during TGCT tumorigenesis.
Function of miRNA372&3 in Embryonic Stem Cells
Our results suggest a link between the expression of
miR-372&3 in embryonic stem cells and their function in
cellular proliferation in these cells. miR-372&3 may facili-
tate rapid growth of stem cells by suppressing the expres-
sion of CDK inhibitors. Intriguingly, Drosophila germ cells
and mouse embryonic stem (ES) cells require miRNAs to
proliferate (Forstemann et al., 2005; Hatfield et al., 2005).
The proliferation defect in Drosophila mutants that lack
miRNAs could be alleviated by loss of dacapo, the Dro-
sophila p21cip1 homolog (Forstemann et al., 2005; Hatfield
et al., 2005).
Our results indicate that due to enhanced tolerance
to oncogenic mutations, deregulated expression of miR-
372&3 predisposes cells for accumulation of carcinogenic
events. Thus, the expression of these miRNAs must be
carefully controlled during differentiation to prevent pro-
gression to cancer. Which factors control miR-371-3 ex-
pression during differentiation and whether their activity
is causally related to development of TGCTs remain to
be explored. Nevertheless, our experiments stress the
importance of a strong downregulation of factors that
maintain rapid cell proliferation, as in the absence of this
downregulation safeguard mechanisms against onco-
gene emergence are functionally impaired.
EXPERIMENTAL PROCEDURES
Constructs
pMSCV-Blast and pMSCV-YFP were made by replacing the puromy-
cin resistance marker of pMSCV-puro (Clontech) with a PCR product
encoding the blasticidin resistance gene from cDNA6/TR (invitrogen)
or YFP from pEYFP-N1 (Clontech), respectively. pRetrosuper (pRS)-
Blast was generated by replacing the 30LTR from pMSCV-Blast with
the 30LTR from pRS-Hyg (Voorhoeve and Agami, 2003).
miR-Vec-Ctrl was made by deleting the MCS and the PGK-promoter
from pMSCV-Blast, followed by insertion of the CMV promoter from
pcDNA-3.1+ and a stuffer DNA derived from the first 211 nt of hTR
downstream of the resistance marker. miR-Vec-YFP was cloned sim-
ilar to miR-Vec-Ctrl, only starting from pMSCV-YFP. pBabe-puro-
RasV12 and pBabe-puro, pMSCV-GFP-st, pRS-GFP, pBabe-H2B-
GFP, pCMV-Cyclin E, pCMV-CDK2, and pBabe-RasV12ERTAM were
described before (Voorhoeve and Agami, 2003; De Vita et al., 2005).
p53kd, p16kd, p14ARFkd, p21cip1kd shRNA constructs were described
before (Voorhoeve and Agami, 2003; Duursma and Agami, 2005).
pMSCV-Blast RASV12-ERTAM was made by subcloning RASV12-ERTAM
into pMSCV-Blast. p21-RFP was produced by cloning p21 to the N
terminus of dsRFP. The constructs encoding Luciferase-30-G6PD wt
and mut were a kind gift of David Bartel (Lewis et al., 2003).
The miRNA minigenes were PCR amplified from genomic human
DNA, cloned downstream of the CMV promoter in miR-Vec, and se-Cquence verified. The primers used for the genomic PCR amplification
of the individual miRNA minigenes, the miR-Vec-cluster and the
miR-Vec mutants, are listed in Figure S3.
LATS2 knockdown constructs were cloned to pRETROSUPER
(pRS)-YFP (Brummelkamp et al., 2002). Targeting sequences are
shown in Figure S3.
miR-Array
Genomic DNA was isolated from BJ/EHT cells with the DNeasy Tissue
Kit (Qiagen). The inserts were recovered by PCR using primers listed
in Figure S3. The PCR product was purified, and 500 ng was labeled
using ULS-Cy3 or Cy5 (Kreatech) and hybridized to the miR-Array ac-
cording to the manufacturers instructions (http://microarrays.nki.nl).
As the amount of spots was too small to normalize automatically, the
red and green signals were normalized by hand in Excel. For each
spot, the log 2 of the red and green ratio as well as the log 2 of the
square root of the product of the two signals were calculated. Outliers
were picked and listed and compared across three independent
experiments.
miRNA Detection
RNase Protection assays were performed using the mirVana miRNA
probe construction and detection kits (Ambion) according to the man-
ufacturers instructions. 2.5 -10 ug of RNA was used per reaction.
Primers to make the RPA probes are listed in Figure S3. The antisense
cyclophilin probe contained nucleotides 46–149 of Accession #
BC013915.
In situ hybridizations were performed with a mix of LNA oligos
against miR-372 and miR-373 (Exiqon) according to the manufac-
turer’s instructions.
Cell Culture and Antibodies
Primary BJ fibroblasts with an ecotropic receptor Neo and pBabe-
puro-hTert (BJ-ET) (Voorhoeve and Agami, 2003) or pBabe-H2BGFP-
hTert (BJ-EHT) (Kolfschoten et al., 2005) were grown in DMEM plus
10% FCS and antibiotics. NCCIT cells were grown in RPMI plus
10% FCS and antibiotics.
Retrovirus was made by calcium-phosphate transduction of Eco-
Pack 2 (Clontech) and harvesting 40 and 64 hr later. BJ cells were
selected with the relevant selective medium 48 hr after transduction
for at least a week. In the case of RASV12-encoding retroviruses, the
selection was continued for the entire duration of the experiment.
Antibodies used were DO-1 (p53), F5 (p21cip1), F235 (RAS), M20 (cy-
clin E), M2 (CDK2) from Santa Cruz Biotechnology, and 3D10 (LATS2)
(Toji et al., 2004). Western blots were scanned and quantified using
AIDA software (Raytek, Sheffield, UK).
Genetic Screen
BJ-EHT cells were transduced with a mixture of 197 miR-Vec vectors,
drug selected for a week, and transduced independently three times
with pBabe-puro-RASV12 or pBabe-puro. Cells from the independent
transductions were propagated for 2 or 3 weeks before genomic DNA
was isolated.
Growth Assay
BJ-EHT cells were transduced with miR-Vec or pRS-blast constructs,
drug selected for a week, transduced with pBabe-Puro-RASV12, and
drug selected for 3 days. 3  105 cells were plated in triplicates in
6 cm dishes and propagated twice a week. SA-b-galactosidase activ-
ity was assessed 10 days after RASV12 transduction, as described
(Kolfschoten et al., 2005). 3 200 cells were scored for b-galactosides
activity.
Soft Agar Assay and Tumorigenic Growth in Mice
BJ-EHT cells were transduced to more than 80% with pMSCV-GFP-st,
pRS-Hyg-p16kd, drug selected, transduced with the various miR-Vec
retroviruses or pRS-Blast-p53kd, drug selected again, and transducedell 124, 1169–1181, March 24, 2006 ª2006 Elsevier Inc. 1179
with pBabe-puro-RASV12. After a week, the cells were either plated in
triplicates in soft agar and macroscopically visible colonies were
counted after 3 weeks or 106 cells were injected subcutaneously to
athymic nude mice.
Cumulative Growth Advantage Assay
BJ/ET cells were transduced with pMSCV-Blast-RASV12-ERTAM, drug
selected, and transduced with miR-Vec–YFP or pRS-GFP constructs.
Efficiency of transduction (starting at 20%–60%) was assessed by
FACS in FL1, and cells were plated with and without 107 M 4-OHT-
Tamoxifen. Cells were propagated, and the percentage of positive
cells was measured twice a week. The relative growth advantage
was calculated as described (Voorhoeve and Agami, 2003).
IP-Kinase Assay and Flow Cytometry
IP-kinase assay and flowcytometry were performed as described in
(Agami and Bernards, 2000).
Expression Array Analysis and Target Prediction
Total RNA from BJ-EHT-st-p16kd-RASV12 cells either expressing
a p53kd shRNA or the miR-Vec-cluster was extracted using Trizol
(Invitrogen) and hybridized to an oligo microarray using a standard pro-
tocol (http://microarrays.nki.nl). The genes that decreased 2-fold or
more were further screened for possible miR-372/3 target sites using
a local version of the TargetScan algorithm (Lewis et al., 2003) with
default parameters (http://www.mekentosj.com/targetscanner).
Supplemental Data
Supplemental Data include seven figures and three tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
124/6/1169/DC1/.
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